Compare EPAM Systems Inc (EPAM) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Illumina, Inc. — how do they compare? EPAM Systems Inc trades at $85.63 (market cap $4.49B), while Illumina, Inc. trades at $188.68 (market cap $28.32B). The key difference: Illumina, Inc. is far larger — about 6.3× EPAM Systems Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| EPAM | ILMN | |
|---|---|---|
Market Cap | $4.49B | $28.32B |
Sector | Technology | Health |
52-Week High | $221.40 | $194.33 |
52-Week Low | $76.04 | $91.00 |
Enterprise Value | $3.74B | $29.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $87.22, up 3.22% today, with strong analyst support (65% buy ratings) and a consensus price target of $128.55 suggesting 47% upside. The stock shows attractive valuation metrics with P/E of 12.35 and P/S of 0.86, though technical indicators signal bearish momentum. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $2.86 exceeding expectations by $0.11. The company maintains solid profitability with 6.96% net margin and 10.93% ROE.
EPAM presents a compelling value opportunity with significant upside potential based on analyst targets, though near-term technical weakness and recent index reclassification from S&P 500 to SmallCap 600 create headwinds. The company's AI transformation expertise and strong client partnerships position it for growth, but investors should monitor execution risks and competitive pressures in the IT services sector.
Illumina (ILMN) trades at $191.20, up 0.61% with strong technical momentum near 52-week highs. The company shows robust fundamentals with consistent earnings beats, 19.42% net margin, and improving cash flow. Recent leadership appointments and product launches support growth narrative. Technical indicators show bullish momentum with support at $188 and resistance at $194.
Outlook remains positive with strong sequencing demand and margin expansion driving recovery. Risks include competition from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings but price target of $174.44 suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
